Additionally, Radhakrishnan et al. [142] indicated that bombesin-conjugated EGCG-loaded SLNs resulted in increased cytotoxicity in MDA-MB-231 breast cancer cells and reduced the tumor size of B16F10 cells compared to EGCG or the bombesin-conjugated EGCG (EB-SLN) group. This evidence concerns the gene GRP and neoplasm.